roche__tree

MIMETAS and Roche to collaborate on drug development

pharmafile | July 6, 2021 | News story | Manufacturing and Production  

MIMETAS and Roche have entered into a collaboration to develop human disease models to characterise novel compounds in inflammatory bowel disease (IBD) and hepatitis B virus infections (HBV).

MIMETAS will be responsible for developing tissue-based disease models and assays in the OrganoPlate, its proprietary organ-on-chip platform that increases predictability of biomarkers and reduces animal use in scientific testing.

Roche will gain access to technology, disease models, and scientific results, as well as receive an option to exclusively license specific disease models and assays for use in drug discovery.

Advertisement

James Sabry, Global Head, Roche Pharma Partnering, said: “This exciting collaboration enables our research and early development group to apply state-of-the-art organ-on-a-chip technology in the modeling of IBD and HBV.

“These models have the potential to improve our understanding of disease biology and transform our drug discovery process.”

Jos Joore, CEO of MIMETAS, said: “The collaboration with Roche leverages our ongoing focus on developing predictive, phenotypic models, preceded by numerous successful projects over the last eight years.

“We will leverage our disease modelling expertise in our world-leading OrganoPlate platform to gain novel insights in IBD and HBV. Working together with the outstanding Roche team, we hope to make a difference in the lives of patients.”

Under the terms of the agreement, MIMETAS is eligible to receive an upfront payment and milestone payments from Roche.

Lilly Subbotin

Related Content

No items found
The Gateway to Local Adoption Series

Latest content